Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04904757 · ClinicalTrials.gov registry record · NA
Contrast-enhanced Spectral Mammography (CESM) Breast Cancer Screening
A NA study of Mammography and Mammographic Breast Density, sponsored by University of Virginia.
- Recruiting
- Registry status
- NA
- Development phase
- 210
- Enrollment target
- 1
- Study location
NCT04904757 is a NA study of Mammography and Mammographic Breast Density that is actively recruiting participants, run by University of Virginia. The registered enrollment target is 210 participants, below the 4,426-participant average among 3 other Mammography trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04904757, a NA study of Mammography and Mammographic Breast Density, is actively recruiting participants, sponsored by University of Virginia.
- RECRUITING
- Registry status
- NA
- Development phase
- 210 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate how well women may adopt a Contrast-enhanced Spectral Mammography (CESM) as their yearly breast screening test compared to the standard 2-D or 3-D mammogram.
Conditions Studied
Interventions
- DEVICE Contrast-enhanced spectral mammography (CESM)
Study Locations (1)
Virginia
- UVA Breast Care Center - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 210 participants |
| Start Date | 2019-09-19 |
| Est. Completion | 2023-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04904757
The ClinicalTrials.gov registry entry for NCT04904757 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 210 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,426-participant average among 3 other Mammography trials with a reported enrollment target (95% lower). The listed sponsor is University of Virginia, which has 449 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Mammography appearing as the primary indexed condition, and to 1 intervention - of which Contrast-enhanced spectral mammography (CESM) is the first listed.
NCT04904757 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT04904757 about?
NCT04904757 is a clinical study titled "Contrast-enhanced Spectral Mammography (CESM) Breast Cancer Screening". The purpose of this study is to evaluate how well women may adopt a Contrast-enhanced Spectral Mammography (CESM) as their yearly breast screening test compared to the standard 2-D or 3-D mammogram.
What is the current status of trial NCT04904757?
This trial is currently recruiting. It is a NA study. The enrollment target is 210 participants. The study started on 2019-09-19. Estimated completion is 2023-06.
What conditions does trial NCT04904757 study?
This clinical trial studies the following conditions: Mammography, Mammographic Breast Density.
What interventions are being tested in trial NCT04904757?
The interventions under investigation include: Contrast-enhanced spectral mammography (CESM) (DEVICE).
Who is sponsoring clinical trial NCT04904757?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04904757 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mammography
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.